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Molecular Model of 
Prion Transmission 
to Humans
Michael Jones, Darren Wight, Rona Barron, 
Martin Jeffrey, Jean Manson, 
Christopher Prowse, James W. Ironside, 
and Mark W. Head
To assess interspecies barriers to transmission of 
transmissible spongiform encephalopathies (TSEs), we in-
vestigated the ability of disease-associated prion proteins 
(PrPd) to initiate conversion of the human normal cellular 
form of prion protein of the 3 major PRNP polymorphic 
variants in vitro. Protein misfolding cyclic amplifi cation 
showed that conformation of PrPd partly determines host 
susceptibility. 
The agents responsible for the transmissible spongiform encephalopathies (TSEs) are called prions. Although 
their precise biochemical composition is a matter of debate, 
they are known to occur in a series of strains, each with 
a characteristic disease phenotype and host range (1). A 
central event in neuropathogenesis of TSEs is conversion 
of the normal cellular form of the prion protein (PrPC) to 
the pathognomonic disease-associated isoform (PrPd) (2). 
In the absence of a known nucleic acid genome, it has been 
proposed that the strain-like properties of different TSE 
agents are encoded by distinct self-propagating conforma-
tional variants (conformers) of PrPd (3). The best developed 
method available for typing these PrPd isoforms uses limited 
proteolysis and classifi cation of the protease-resistant prion 
protein (PrPres) in terms of the sizes of the nonglycosylated 
fragment(s) produced and the ratio of the 3 possible glyco-
forms (3). If distinct conformers and glycotypes of PrPd are 
responsible for diversity of prion strains, then they would 
be expected to be able to impose these molecular charac-
teristics onto PrPC of the same amino acid sequence (when 
transmitted or replicating within a species) and onto PrPC 
of a different primary sequence (when transmitted between 
species). In support of this theory, the agent responsible for 
the TSE of cattle, called bovine spongiform encephalopa-
thy (BSE), the accepted cause of variant Creutzfeldt-Jakob 
disease (vCJD) in humans (4), has been shown to be trans-
missible to at least 7 species (1), resulting in propagation of 
PrPd that retains the characteristic molecular signature of 
the original BSE prion strain (5–7).
Current thinking favors a seeded polymerization mod-
el for the conversion of PrPC into PrPd, which has led to the 
development of several cell-free in vitro conversion model 
systems (8). One such system is protein misfolding cyclic 
amplifi cation (PMCA) (9), in which small amounts of PrPd 
introduced (seeded) into substrate containing excess PrPC 
and other essential conversion cofactors can be amplifi ed 
to readily detectable levels by sequential cycles of sonica-
tion and incubation. We have previously reported that the 
molecular characteristics, electrophoretic mobility, and 
glycoform ratio of the PrPres associated with the vCJD PrPd 
conformer were faithfully reproduced by PMCA (10). How-
ever, the effi ciency of amplifi cation achieved depended on 
the substrate’s prion protein gene codon 129 (PRNP-129) 
genotype. The most effi cient amplifi cation was achieved 
in a methionine homozygous (PRNP-129MM) substrate; 
the least effi cient, in a valine homozygous (PRNP-129VV) 
substrate. To estimate the molecular component of trans-
mission barriers for particular TSE agents between species, 
we used PMCA reactions to amplify PrPd associated with 
vCJD (10), bovine BSE (11), ovine scrapie (12), and exper-
imental ovine BSE (13) and substrates prepared from hu-
manized transgenic mouse brain tissue expressing each of 
the 3 main PRNP polymorphic variants found in Caucasian 
human populations (PRNP-129MM, MV, and VV) (14). 
The Study
We prepared seed and substrate homogenates as 10% 
(wt/vol) homogenates in PMCA conversion buffer (10). 
Seed homogenates were diluted into substrate homoge-
nates so that all PMCA reactions contained equivalent 
amounts of PrPd based on the PrPres levels in each seed ho-
mogenate. PrPres levels were determined by Western blot 
titration that used monoclonal antibody (MAb) 6H4 after 
limited proteinase K digestion. The reaction mixes were 
split into 2 aliquots; 1 aliquot was stored immediately at 
–80°C (−PMCA), and the other was subjected to 48 cycles 
of PMCA (+PMCA) (10). To assess the degree of PrPd am-
plifi cation achieved from each seed in each substrate, the 
samples −/+ PMCA were subjected to limited proteinase K 
digestion, and PrPres was detected by Western blotting with 
MAb 6H4 (which recognizes human, bovine, and ovine 
PrP) and MAb 3F4 (which selectively recognizes only hu-
man PrP and would therefore specifi cally identify PrPres 
formed from human PrPC).
Using MAb 6H4 to probe Western blots, we noted 
amplifi cation of vCJD, bovine BSE, and ovine BSE PrPres 
in the PRNP-129MM substrate (Figure 1, panel A, top) 
but not in the PRNP-129VV substrate (Figure 1, panel A, 
bottom). Semiquantitative assessment of these Western 
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blots by densitometry showed that the degree of amplifi -
cation of vCJD PrPres was considerably greater than that 
of bovine or ovine BSE in the PRNP-129MM substrate 
(Figure 2, panel A). A more sensitive and discriminatory 
Western blot conducted by using MAb 3F4 confi rmed ef-
fi cient amplifi cation of vCJD, bovine BSE, and ovine BSE 
PrPres in the PRNP-129MM substrate (Figure 1, panel B, 
top), weaker amplifi cation in the PRNP-129MV substrate 
(Figure 1, panel B, middle), and little, if any, amplifi ca-
tion in the PRNP-129VV substrate (Figure 1, panel B, 
bottom). In all substrates, the amplifi ed PrPres retained the 
electrophoretic mobility and glycoform ratio associated 
with BSE-related PrPres. No amplifi cation of ovine scrapie 
PrPres was evident after PMCA in any of the PRNP human-
ized transgenic mouse brain substrates (Figure 1, panels A, 
B). The difference between ovine scrapie and ovine BSE 
in ability to seed amplifi cation in PRNP-129MM substrate 
was a robust phenomenon evident in brain samples from 
3 different ARQ/ARQ sheep with each disease (Figure 2, 
panel B). However, failure of the ovine scrapie seed to am-
plify was not caused by a general lack of competence to 
do so or by inappropriate amplifi cation conditions because 
robust amplifi cation of ovine scrapie PrPres was evident af-
ter PMCA in a substrate prepared from normal ARQ/ARQ 
sheep brain (Figure 2, panel C).
Conclusions
Our results are best appreciated in terms of the mo-
lecular interaction between seed PrPd and substrate PrPC, 
specifi cally the species-specifi c amino acid sequence and 
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Figure 1. Amplifi cation of PrPd by PMCA from bovine BSE, ovine scrapie, experimental ovine BSE, and human vCJD brain homogenates 
in substrate homogenates prepared from humanized transgenic mouse brain tissue expressing PrP of each human prion protein gene 
codon 129 (PRNP-129) genotype. A) Amplifi cation of each PrPd type, as determined by Western blotting using MAb 6H4 to detect PrPres 
after limited proteinase K digestion, in a PRNP-129MM substrate (top panel, 3-min exposure), a PRNP-129MV substrate (middle panel, 
3-min exposure), and a PRNP-129VV substrate (bottom panel, 3-min exposure). B) Amplifi cation of each PrPd type, as determined 
by Western blotting using MAb 3F4 to detect PrPres derived from human PrP after limited proteinase K digestion, in a PRNP-129MM 
substrate (top panel, 30-s exposure), a PRNP-129MV substrate (middle panel, 3-min exposure), and a PRNP-129VV substrate (bottom 
panel, 10-min exposure). Limited proteinase K digestion and Western blotting were conducted out as previously described (11). MAb 6H4 
(Prionics, Schlieren-Zurich, Switzerland) and MAb 3F4 (Dako, Ely, Cambridgeshire, UK) were used at a fi nal concentration of 50 ng/mL. 
PrPd, disease-associated prion protein; PMCA, protein misfolding cyclic amplifi cation; BSE, bovine spongiform encephalopathy; vCJD, 
variant Creutzfeldt-Jakob disease; MAb, monoclonal antibody; PrPres, protease-resistant prion protein; MM, methionine homozygous; MV, 
methionine/valine heterozygous; VV, valine homozygous. Values are in kilodaltons.
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PRNP polymorphic status of PrPC and PrPd and the PrPd 
conformers involved (Table). Regardless of the seed PrP 
amino acid sequence, the PrPd conformers associated with 
bovine BSE, ovine BSE, and human vCJD were amplifi ed 
in the humanized mouse substrate and displayed similar 
PRNP-129 genotype preferences (PRNP-129MM >PRNP-
129MV >PRNP-129VV). In contrast, the PrPd conformer 
associated with the ovine scrapie strain, although sharing 
the same PrP amino acid sequence as the PrPd in ovine 
BSE, could not be amplifi ed in any of the PRNP humanized 
mouse substrates but could be amplifi ed in a sheep brain 
substrate. These observations are consistent with confor-
mation of a TSE agent’s PrPd (rather than solely its amino 
acid sequence) having a role in determining the susceptibil-
ity of a host’s PrPC to conversion. They similarly suggest 
that these molecular factors could in turn have a powerful 
infl uence on disease susceptibility and incubation time.
To date, all clinical cases of vCJD have occurred in 
persons with the PRNP-129MM genotype, as might be pre-
dicted from the effi ciency of amplifi cation of BSE-related 
PrPd shown here. Extrapolating from these results, one 
would predict that the next genotypic group most likely to 
show susceptibility to the BSE agent would be heterozy-
gous (MV) at codon 129 of the PRNP gene, as previously 
suggested from the corresponding in vivo transmission 
studies (14). 
In the wake of BSE epidemics in the United Kingdom 
and elsewhere, enhanced surveillance has identifi ed appar-
ently new TSEs (15), raising concerns regarding animal 
and human health. PMCA with suitable substrate sources 
could provide a rapid way to estimate the molecular com-
ponent of transmission barriers for particular TSE agents 
between species, including humans. These estimates could 
thus indicate whether, like classical scrapie, the agents rep-
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009 2015 
Figure 2. A) Semiquantitative densitometric analysis (optical density × area in mm2) of Western blot data (Figure 1, panel A, top panel), 
showing the amplifi cation factors (+PMCA/−PMCA) obtained for all 4 seeds (bovine BSE, ovine scrapie, ovine BSE, and human vCJD in 
the PRNP-129MM substrate. B) Amplifi cation of PrPd associated with ovine BSE (left) and ovine scrapie (right) from each of 3 different 
sheep in PRNP-129MM substrate as determined by Western blotting using MAb 3F4 to detect PrPres after limited proteinase K digestion. 
Substrate was seeded with brain homogenates prepared from sheep with confi rmed scrapie and BSE such that each PMCA reaction 
mix contained an equivalent amount of PrPd according to detection of PrPres by Western blot titration after limited proteinase K digestion. 
PRNP-129MM substrate seeded with vCJD brain homogenate was included as a positive control in each experiment. C) Amplifi cation 
of PrPd associated with ovine scrapie and BSE in substrates prepared from PRNP-129 methionine homozygous humanized transgenic 
mouse brain tissue (MM substrate) and NSB substrate. Substrates were prepared as 10% (wt/vol) homogenates in PMCA conversion 
buffer (10). Each substrate was seeded with brain homogenates prepared from sheep with confi rmed scrapie and BSE so that each PMCA 
reaction mix contained an equivalent amount of PrPd as determined by detection of PrPres by Western blot titration after limited proteinase 
K digestion. Reaction mixes were divided into 2 lots: 1 was stored immediately at –80°C (−PMCA) and the other was subjected to 48 cycles 
of PMCA (+PMCA) by using standard conditions (10). After limited proteinase K digestion, PrPres in samples −/+PMCA was detected by 
Western blotting using MAb 6H4. PMCA, protein misfolding cyclic amplifi cation; BSE, bovine spongiform encephalopathy; vCJD, variant 
Creutzfeldt-Jakob disease; MM, methionine homozygous; PrPd, disease-associated prion protein; MAb, monoclonal antibody; PrPres, 
protease-resistant prion protein; NSB, normal ARQ/ARQ sheep brain tissue. Values on the left in panels B and C are in kilodaltons.
resent little risk for human health or whether, like classical 
BSE, they represent cause for concern.
This work was funded by the European Network of Excel-
lence NeuroPrion (FOOD-CT-2004-506579), the Scottish Na-
tional Blood Transfusion Services, and the Chief Scientist Of-
fi ce of the Scottish Government (CZB/4/357). The National CJD 
Surveillance Unit is funded by the Department of Health and the 
Scottish Government.
Dr Jones is a postdoctoral research fellow at the National 
CJD Surveillance Unit, University of Edinburgh. His primary re-
search interests are the application of in vitro PrPd amplifi cation 
techniques, such as PMCA, to prion disease research in general 
and incorporation of these techniques into a confi rmatory screen-
ing assay to detect vCJD-associated PrPd in human plasma as a 
surrogate marker of vCJD infectivity in blood.
References
  1.  Bruce ME. TSE strain variation. Br Med Bull. 2003;66:99–108. 
DOI: 10.1093/bmb/66.1.99
  2.  Prusiner SB. Prions. Proc Natl Acad Sci U S A. 1998;95:13363–83. 
DOI: 10.1073/pnas.95.23.13363
  3.  Collinge J, Clark AR. A general model of prion strains and their 
pathogenicity. Science. 2007;318:930–6. DOI: 10.1126/science.
1138718
  4.  Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alpero-
vitch A, et al. Lancet. 1996;347:921–5. DOI: 10.1016/S0140-6736
(96)91412-9
  5.  Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular analy-
sis of prion strain variation and the aetiology of ‘new variant’ CJD. 
Nature. 1996;383:685–90. DOI: 10.1038/383685a0
  6.  Head MW, Bunn TJ, Bishop MT, McLoughlin V, Lowrie S, McKim-
mie J, et al. Prion protein heterogeneity in sporadic but not vari-
ant Creutzfeldt-Jakob disease: UK cases 1991–2002. Ann Neurol. 
2004;55:851–9. DOI: 10.1002/ana.20127
  7.  Eloit M, Adjou K, Coulpier M, Fontaine JJ, Hamel R, Lilin T, et al. 
BSE agent signatures in a goat. Vet Rec. 2005;156:523–4.
  8.  Supattapone S. Prion protein conversion in vitro. J Mol Med. 
2004;82:348–56. DOI: 10.1007/s00109-004-0534-3
  9.  Saborio GP, Permanne B, Soto C. Sensitive detection of pathological 
prion protein by cyclic amplifi cation of protein misfolding. Nature. 
2001;411:810–3. DOI: 10.1038/35081095
10.  Jones M, Peden AH, Prowse CV, Groner A, Manson JC, Turner ML, 
et al. In vitro amplifi cation and detection of variant Creutzfeldt-Jakob 
disease PrPSc. J Pathol. 2007;213:21–6. DOI: 10.1002/path.2204
11.  Yull HM, Ritchie DL, Langeveld JP, van Zijderveld FG, Bruce 
ME, Ironside JW, et al. Detection of type 1 prion protein in vari-
ant Creutzfeldt-Jakob disease. Am J Pathol. 2006;168:151–7. DOI: 
10.2353/ajpath.2006.050766
12  Jeffrey M, Martin S, Thomson JR, Dingwall WS, Begara-McGorum 
I, Gonzalez L. Onset and distribution of tissue prp accumulation 
in scrapie-affected Suffolk sheep as demonstrated by sequential 
necropsies and tonsillar biopsies. J Comp Pathol. 2001;125:48–57. 
13.  Gonzalez L, Chianini F, Martin S, Siso S, Gibbard L, Reid HW, et al. 
Comparative titration of experiment ovine BSE infectivity in sheep 
and mice. J Gen Virol. 2007;88:714–7. DOI: 10.1099/vir.0.82426-0
14.  Bishop MT, Hart P, Aitchison L, Baybutt HN, Plinston C, Thomson 
V, et al. Predicting susceptibility and incubation time of human-to-
human transmission of vCJD. Lancet Neurol. 2006;5:393–8. DOI: 
10.1016/S1474-4422(06)70413-6
15.  Manson JC, Cancellotti E, Hart P, Bishop MT, Barron RM. The 
transmissible spongiform encephalopathies: emerging and declin-
ing epidemics. Biochem Soc Trans. 2006;34:1155–8. DOI: 10.1042/
BST0341155
Address for correspondence: Michael Jones, National CJD Surveillance 
Unit, School of Molecular and Clinical Medicine, University of Edinburgh, 
Western General Hospital, Edinburgh, Scotland EH4 2XU, UK; email: 
mjones1@staffmail.ed.ac.uk
DISPATCHES
2016 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 12, December 2009
Table. Summary of the properties of the sources used in PMCA of vCJD, bovine BSE, ovine scrapie, and experimental ovine BSE 
PrPres*
Species Bovine† Human‡ Ovine§ Ovine§
Disease BSE vCJD BSE Scrapie
Tissue Brain Brain Brain Brain
PRNP amino acid sequence Bovine Human Ovine Ovine
PRNP polymorphism 140MM 129MM ARQ/ARQ (132MM) ARQ/ARQ (132MM)
Seed
homogenate
PrPd “conformer” BSE BSE BSE Scrapie
Species Mouse Mouse Mouse Mouse
Tissue Brain Brain Brain Brain
PrP amino acid sequence Human Human Human Human
PRNP-129 polymorphism MM, MV, and VV MM, MV, and VV MM, MV, and VV MM, MV, and VV 
Substrate
homogenate¶ 
Background genotype 129 Ola prnp/ 129 Ola prnp/ 129 Ola prnp/ 129 Ola prnp/
*PMCA, protein misfolding cyclic amplification; vCJD, variant Creutzfeldt-Jakob disease; BSE, bovine spongiform encephalopathy; PrPres, protease-
resistant prion protein; PrPd, disease-associated prion protein; MM, methionine homozygous; MV, methionine/valine heterozygous; VV, valine 
homozygous.  
†Bovine brain tissue was sampled from brain tissue taken from a Friesian cow with terminal BSE (11). 
‡Human brain tissue (frontal cortex) was sampled from a frozen half brain that had been collected at autopsy with the appropriate consent for tissue 
retention and research use from a patient methionine homozygous at PRNP codon 129, who received a final diagnosis of definite vCJD by established 
criteria. Ethical approval for its use in this study was covered by LREC 2000/4/157 (J.W.I.). 
§Both the ovine scrapie (12) and ovine BSE (13) brain tissue (hind brain) were sampled from clinically sick sheep. The distinctive disease phenotypes 
were confirmed by histopathologic, immunohistochemical, and Western blot characteristics. 
¶Frozen half brains from inbred transgenic mouse lines expressing human PrP of the 3 major PRNP codon-129 genotypes (MM, MV, VV) were used to 
prepare substrate homogenates. These mice had identical genetic backgrounds, were produced to express human PrP by direct replacement of the 
murine PrP gene, and all expressed equivalent amounts of human PrP regardless of the PRNP-129 genotype (14). The transgenic mice were bred under 
license to the UK Home Office in accordance with the UK Animals (Scientific Procedures) Act of 1986, and the use of brain tissue from these mice was 
reviewed and approved by the local Ethics Review Committee. 
